ab science sa (AB:EN Paris)
ab science sa (AB) Snapshot
|
Open
€17.99
|
Previous Close
€18.08
|
|
|
Day High
€18.06
|
Day Low
€17.68
|
|
|
52 Week High
10/31/12 - €23.00
|
52 Week Low
07/13/12 - €9.02
|
|
|
Market Cap
560.9M
|
Average Volume 10 Days
42.5K
|
|
|
EPS TTM
€-0.34
|
Shares Outstanding
31.7M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
ab science sa (AB) Related Businessweek News
No Related Businessweek News Foundab science sa (AB) Details
AB Science S.A., a pharmaceutical company, engages in the discovery, development, and commercialization of protein kinase inhibitors for use in human and veterinary medicine in the United States and Europe. The company focuses on therapies for the treatment of cancer, inflammatory diseases, and central nervous system diseases. Its lead compound is Masitinib, a tyrosine kinase inhibitor that targets mast cells and selected kinases, including c-Kit, PDGR, and Lyn. The company’s pipeline includes three Phase III clinical trials ongoing in pancreatic cancer, GIST, and mastocytosis and eight Phase II clinical trials completed. It markets Masitinib under the brand name Masivet for the veterinary market in Europe. The company’s other tyrosine kinase inhibitors that plan to initiate preclinical development include KIT816 for aggressive mastocytosis, seminoma, and acute myeloid leukemia; VEGFR2 for kidney cancer; and Bcr-Abl/Lyn for chronic myeloid leukemia. AB Science S.A. was founded in 2001 and is headquartered in Paris, France.
ab science sa (AB) Key Developments
AB Science S.A. announced consolidated earnings results for the year ended Dec. 31, 2012 and consolidated revenue results for the first quarter of 2013. Total revenues for the year 2012 amounted to EUR 1,304,000 compared with EUR 1,104,000 in the previous year. Operating loss amounted to EUR 10,613,000 compared with EUR 9,716,000 reported in 2011. Net loss attributable to equity holders of the parent company was EUR 10,985,000 or EUR 0.34 per diluted share against EUR 9,651,000 or EUR 0.31 per diluted share reported last year. Net cash used in operating activities was EUR 324,000 against EUR 433,000 and acquisitions of financial assets was EUR 8,500,000 against EUR 17,000,000 reported last year. AB Science revenues in the first quarter of 2013 amounted to EUR 571,000 versus EUR 321,000 in the first quarter of 2012, up 78%. These revenues derive from the commercial exploitation of masitinib in veterinary medicine in Europe and in the United States.
AB Science S.A. will be added to SBF 120 Index
AB Science S.A. will be removed from CAC Small Index
| Recently Viewed | |||
| AB:FP | €17.71 EUR | -0.37 |  |
| Company | Last | Change |
| Oasmia Pharmaceutical AB | kr10.50 SEK | -0.20 |
| Pfizer Inc | $28.96 USD | -0.29 |
| View Industry Companies | ||
Industry Analysis
AB
Industry Average
| Valuation | AB | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 426.1x |
|
| Price/Book | 113.9x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 383.7x |
|
Post a JobJobs
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
- Thornton, CO | IntuitPosted: Apr 29
Sponsored Financial Commentaries
Sponsored Links
To contact AB SCIENCE SA, please visit www.ab-science.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
